Loading...
XNASARDX
Market cap1.20bUSD
Jan 10, Last price  
5.07USD
1D
-5.06%
1Q
-16.06%
Jan 2017
-64.30%
IPO
-64.57%
Name

Ardelyx Inc

Chart & Performance

D1W1MN
XNAS:ARDX chart
P/E
—
P/S
9.65
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.29%
Rev. gr., 5y
116.66%
Revenues
124m
+138.61%
5,410,00028,928,00031,623,00024,026,00024,026,00042,000,0002,607,0005,281,0007,571,00010,097,00052,158,000124,456,000
Net income
-66m
L-1.70%
-9,785,000-6,564,000-3,214,000-29,621,000-112,387,000-64,339,000-91,298,000-94,940,000-94,313,000-158,165,000-67,207,000-66,067,000
CFO
-90m
L+28.09%
21,980,0001,811,00013,397,000-71,840,000-92,534,000-65,190,000-70,274,000-76,484,000-81,435,000-152,551,000-70,044,000-89,717,000
Earnings
Feb 20, 2025

Profile

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
URL
https://www.ardelyx.com/
IPO date
Jun 19, 2014
Employees
133
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
124,456
138.61%
52,158
416.57%
Cost of revenue
53,331
115,917
Unusual Expense (Income)
NOPBT
71,125
(63,759)
NOPBT Margin
57.15%
Operating Taxes
547
8
Tax Rate
0.77%
NOPAT
70,578
(63,767)
Net income
(66,067)
-1.70%
(67,207)
-57.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
119,236
71,827
BB yield
-8.77%
-15.88%
Debt
Debt current
8,870
30,605
Long-term debt
57,707
15,604
Deferred revenue
8,644
9,025
Other long-term liabilities
20,179
2,229
Net debt
(117,722)
(77,700)
Cash flow
Cash from operating activities
(89,717)
(70,044)
CAPEX
(344)
(55)
Cash from investing activities
(131,248)
18,415
Cash from financing activities
146,295
75,341
FCF
54,209
(59,171)
Balance
Cash
184,299
123,909
Long term investments
Excess cash
178,076
121,301
Stockholders' equity
(845,957)
(780,171)
Invested Capital
1,102,013
926,214
ROIC
6.96%
ROCE
27.78%
EV
Common stock shares outstanding
219,331
158,690
Price
6.20
117.54%
2.85
159.09%
Market cap
1,359,854
200.68%
452,267
294.56%
EV
1,242,132
374,567
EBITDA
72,417
(62,615)
EV/EBITDA
17.15
Interest
8,874
5,073
Interest/NOPBT
12.48%